Ed Farrell Appointed CEO of LEX Diagnostics

LEX Diagnostics has a new leader.

The company has appointed Ed Farrell as its new CEO. “On behalf of the company, I welcome Ed to LEX Diagnostics. He brings an abundance of operational experience from his successful career spanning the diagnostics and medtech industry,” former CEO and current Board Chair Dr. Andrew Baker-Campbell said. “We are confident Ed will drive the translation of our technology into a commercial product. I look forward to continuing my role as chair of the board, overseeing the strategy of this molecular diagnostics company.”
 
Farrell brings to the position more than 25 years of life science experience gained through senior industry roles with an emphasis on medical devices and diagnostics. Immediately prior to joining LEX Diagnostics, Farrell was chief operating officer (COO) of Klay Biotech. From 2013 to 2021 he was president/COO of Quotient Ltd., where he led the development and realization of the MosaiQ platform from concept to commercialization. He also played a significant role with Quotient’s IPO on Nasdaq. Before Quotient, Farrell held senior positions in operations in the United Kingdom, United States, and Ireland with Siemens Healthcare Diagnostics.

Farrell earned a degree in mechanical engineering and a master’s degree in engineering science from University College, Dublin.

“I’m thrilled to join the team at LEX and to work toward launching our five-minute multiplex PCR test. Our goal is to rapidly bring our innovative thermocycling technology to the healthcare market, improving patient care worldwide and opening the door to syndromic testing by bringing the necessary clinical insights to healthcare providers within minutes,” Farrell said in his first formal statement as CEO.
 
LEX Diagnostics is a privately held U.K. molecular diagnostics company developing products to meet its vision of a five-minute multiplex PCR test designed to enhance patient care by delivering clinical insights within minutes. The company’s thermocycling technology delivers accurate PCR results in a fraction of the time and cost of devices available today, according to the company. The company’s five-minute multiplex PCR test is designed to quickly determine the presence of infectious diseases including SARS-CoV-2 (COVID-19), Influenza, Strep A, and RSV.